Innovation Pharmaceuticals has reported that its drug candidate, Brilacidin, showed broad-spectrum antiviral activity against Covid-19 in an in vitro study.
A non-peptidic defensin-mimetic drug, Brilacidin is presently being analysed in a clinical trial for the treatment of Covid-19 under fast track status from the US Food and Drug Administration (FDA).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe latest data is based on the study carried out by researchers at the George Mason University (GMU)/National Center for Biodefense and Infectious Diseases in the US.
As per the research, Brilacidin showed the ability to hinder the SARS-CoV-2 virus in various human cell lines, including Caco-2, which is primary lung fibroblasts.
The drug candidate also hindered alphaviruses such as Venezuelan equine encephalitis virus, Eastern equine encephalitis virus and Rift Valley fever virus, a bunyavirus.
Innovation noted that the results support potent broad-spectrum antiviral activity exerted by Brilacidin using its ability to interrupt viral integrity and stop viral entry.
Brilacidin primary Investigator at GMU Aarthi Narayanan said: “Brilacidin continues to show a consistent ability in the laboratory to inhibit different contagious viruses, regardless of viral strain and in a cell type-independent manner.
“Our scientific team looks forward to exploring Brilacidin further as we investigate the breadth of its antiviral profile.”
In March, a machine learning model used to analyse 1,482 compounds detected Brilacidin among the top 3% that can potentially be most effective against SARS-CoV-2, based on its molecular properties.
Brilacidin is undergoing a randomised, blinded, placebo-controlled Phase II study in 120 hospitalised patients with moderate-to-severe Covid-19.
The trial with a parallel-group design is evaluating the efficacy and safety of the drug candidate in these subjects.
Innovation Pharmaceuticals CEO Leo Ehrlich said: “The Covid-19 pandemic, with infections, hospitalisations and deaths once again spiking, is a stark reminder that the world is in need of effective broad-spectrum antiviral countermeasures that can be readily deployed to help mitigate viral outbreaks.
“Our Phase II Brilacidin clinical trial in hospitalised Covid-19 patients was fully enrolled.”
